919-SMG1 Inhibition and Expansion of Cancer Immunopeptidome

The paper explores how inhibiting the nonsense-mediated mRNA decay (NMD) pathway can reveal a hidden reservoir of cancer antigens to improve immunotherapy. By targeting the SMG1 kinase, researchers successfully stabilized aberrant genetic transcripts that the body normally destroys before they can be processed by the immune system. This process reshapes the tumor immunopeptidome, introducing non-canonical neoantigens that make "cold" tumors appear more like high-mutation cancers to the immune system. Experimental results demonstrated that this intervention triggers T cell activation and enhances the effectiveness of checkpoint blockade treatments in both patient-derived models and vivo studies. Ultimately, the research identifies NMD inhibition as a powerful strategy to expose previously inaccessible targets and drive a robust anti-tumor response across various cancers.

References:

• Vendramin R, Fu H, Patel S F, et al. Nonsense-mediated mRNA decay inhibition reshapes the cancer immunopeptidome[J]. Immunity, 2026.